- Home
- SEVN vs ELDN Comparison
SEVN vs ELDN Comparison
Compare SEVN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ELDN
- Stock Information
- Founded
- SEVN 1986
- ELDN 2004
- Country
- SEVN United States
- ELDN United States
- Employees
- SEVN N/A
- ELDN N/A
- Industry
- SEVN Real Estate Investment Trusts
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- ELDN Health Care
- Exchange
- SEVN Nasdaq
- ELDN Nasdaq
- Market Cap
- SEVN 173.7M
- ELDN 178.4M
- IPO Year
- SEVN N/A
- ELDN N/A
- Fundamental
- Price
- SEVN $12.07
- ELDN $2.68
- Analyst Decision
- SEVN Strong Buy
- ELDN Strong Buy
- Analyst Count
- SEVN 3
- ELDN 2
- Target Price
- SEVN $14.75
- ELDN $12.50
- AVG Volume (30 Days)
- SEVN 46.1K
- ELDN 609.3K
- Earning Date
- SEVN 07-28-2025
- ELDN 08-18-2025
- Dividend Yield
- SEVN 11.60%
- ELDN N/A
- EPS Growth
- SEVN N/A
- ELDN N/A
- EPS
- SEVN 1.15
- ELDN N/A
- Revenue
- SEVN $30,074,000.00
- ELDN N/A
- Revenue This Year
- SEVN $7.45
- ELDN N/A
- Revenue Next Year
- SEVN $1.12
- ELDN N/A
- P/E Ratio
- SEVN $10.50
- ELDN N/A
- Revenue Growth
- SEVN N/A
- ELDN N/A
- 52 Week Low
- SEVN $10.18
- ELDN $2.30
- 52 Week High
- SEVN $14.66
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- SEVN 57.51
- ELDN 38.39
- Support Level
- SEVN $11.78
- ELDN $2.60
- Resistance Level
- SEVN $12.06
- ELDN $2.91
- Average True Range (ATR)
- SEVN 0.24
- ELDN 0.17
- MACD
- SEVN 0.03
- ELDN -0.02
- Stochastic Oscillator
- SEVN 83.33
- ELDN 16.98
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.